U.S. FDA approves AbbVie’s once-daily pill for Parkinson’s disease
Washington: The United States Food and Drug Administration has approved AbbVie’s treatment for Parkinson’s disease in adults, the regulator’s website showed on Friday, September 25, 2026.
The drug, tavapadon, comes as a once-a-day pill. AbbVie gained access to it through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.
The regulator’s nod was based on data from AbbVie’s late-stage trial program which showed the drug improved symptoms in patients with the disease.
The approval marks a significant addition to treatment options for Parkinson’s disease, which affects millions worldwide.
